Cargando…
Genetic heterogeneity in response to adenovirus gene therapy
BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to anot...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC155537/ https://www.ncbi.nlm.nih.gov/pubmed/12697054 http://dx.doi.org/10.1186/1471-2199-4-4 |
_version_ | 1782120755353354240 |
---|---|
author | Lefesvre, Pierre Attema, Joline Lemckert, Angelique Havenga, Menzo Bekkum, Dirk van |
author_facet | Lefesvre, Pierre Attema, Joline Lemckert, Angelique Havenga, Menzo Bekkum, Dirk van |
author_sort | Lefesvre, Pierre |
collection | PubMed |
description | BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to another. This study was initiated to determine the molecular mechanism causing the difference: hepatic transfection, transcription or translation. For this purpose different doses of Ad5 luciferase and Ad5 LacZ were intravenously injected into Brown Norway rats and Wag/Rij rats, two strains that differ by a factor of 10 in encoded protein levels. The proportion of LacZ positive hepatocytes, the adenoviral DNA, specific transgenic RNA and luciferase protein were compared in the two strains. RESULTS: The number of transduced hepatocytes and the amounts of Ad5 DNA in the livers was similar in both strains, whereas the Brown Norway rats produced 8 to 10 times more of both vector encoded proteins and of transgene mRNA than the Wag/Rij rats. CONCLUSIONS: It is concluded that the difference between strains in vector encoded protein expression is due to different transcriptional events. No evidence was obtained to suggest that the differences are related to liver damage influenced by vector toxicity or immune reactions. |
format | Text |
id | pubmed-155537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1555372003-05-17 Genetic heterogeneity in response to adenovirus gene therapy Lefesvre, Pierre Attema, Joline Lemckert, Angelique Havenga, Menzo Bekkum, Dirk van BMC Mol Biol Research Article BACKGROUND: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the encoded protein is produced in the hepatocytes. We observed, as have others, that the early expression levels of the vector encoded protein vary, greatly, within a species, from one animal strain to another. This study was initiated to determine the molecular mechanism causing the difference: hepatic transfection, transcription or translation. For this purpose different doses of Ad5 luciferase and Ad5 LacZ were intravenously injected into Brown Norway rats and Wag/Rij rats, two strains that differ by a factor of 10 in encoded protein levels. The proportion of LacZ positive hepatocytes, the adenoviral DNA, specific transgenic RNA and luciferase protein were compared in the two strains. RESULTS: The number of transduced hepatocytes and the amounts of Ad5 DNA in the livers was similar in both strains, whereas the Brown Norway rats produced 8 to 10 times more of both vector encoded proteins and of transgene mRNA than the Wag/Rij rats. CONCLUSIONS: It is concluded that the difference between strains in vector encoded protein expression is due to different transcriptional events. No evidence was obtained to suggest that the differences are related to liver damage influenced by vector toxicity or immune reactions. BioMed Central 2003-04-05 /pmc/articles/PMC155537/ /pubmed/12697054 http://dx.doi.org/10.1186/1471-2199-4-4 Text en Copyright © 2003 Lefesvre et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Lefesvre, Pierre Attema, Joline Lemckert, Angelique Havenga, Menzo Bekkum, Dirk van Genetic heterogeneity in response to adenovirus gene therapy |
title | Genetic heterogeneity in response to adenovirus gene therapy |
title_full | Genetic heterogeneity in response to adenovirus gene therapy |
title_fullStr | Genetic heterogeneity in response to adenovirus gene therapy |
title_full_unstemmed | Genetic heterogeneity in response to adenovirus gene therapy |
title_short | Genetic heterogeneity in response to adenovirus gene therapy |
title_sort | genetic heterogeneity in response to adenovirus gene therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC155537/ https://www.ncbi.nlm.nih.gov/pubmed/12697054 http://dx.doi.org/10.1186/1471-2199-4-4 |
work_keys_str_mv | AT lefesvrepierre geneticheterogeneityinresponsetoadenovirusgenetherapy AT attemajoline geneticheterogeneityinresponsetoadenovirusgenetherapy AT lemckertangelique geneticheterogeneityinresponsetoadenovirusgenetherapy AT havengamenzo geneticheterogeneityinresponsetoadenovirusgenetherapy AT bekkumdirkvan geneticheterogeneityinresponsetoadenovirusgenetherapy |